Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-29

Clinical Trial Update: Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating nintedanib with weekly docetaxel in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DOCETAXEL (DOCETAXEL)
  • Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2021-01-29